Stockscreener 앱 받기
13.00
1.01%
0.13
시간 외 거래:
13.26
0.26
+2.00%
전일 마감가:
$12.87
열려 있는:
$12.89
하루 거래량:
501.89K
Relative Volume:
0.64
시가총액:
$847.28M
수익:
-
순이익/손실:
$-119.67M
주가수익비율:
-4.7619
EPS:
-2.73
순현금흐름:
$-97.30M
1주 성능:
-4.87%
1개월 성능:
-6.81%
6개월 성능:
+32.52%
1년 성능:
+16.38%
1일 변동 폭
$12.70
$13.09
1주일 범위
$12.70
$13.81
52주 변동 폭
$8.241
$18.38
Mineralys Therapeutics Inc Stock (MLYS) Company Profile
명칭
Mineralys Therapeutics Inc
전화
(888) 378-6240
주소
150 N. RADNOR CHESTER ROAD, RADNOR
MLYS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MLYS
Mineralys Therapeutics Inc
|
13.00 | 877.26M | 0 | -119.67M | -97.30M | -2.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-11 | 개시 | Jefferies | Hold |
| 2024-07-10 | 개시 | H.C. Wainwright | Buy |
| 2024-04-02 | 개시 | Goldman | Buy |
| 2023-03-07 | 개시 | BofA Securities | Buy |
| 2023-03-07 | 개시 | Credit Suisse | Outperform |
| 2023-03-07 | 개시 | Evercore ISI | Outperform |
| 2023-03-07 | 개시 | Guggenheim | Buy |
| 2023-03-07 | 개시 | Stifel | Buy |
| 2023-03-07 | 개시 | Wells Fargo | Overweight |
모두보기
Mineralys Therapeutics Inc 주식(MLYS)의 최신 뉴스
Mineralys Therapeutics to Announce Q2 Financial Results on August 12 - MSN
Mineralys Therapeutics CFO & Secretary Adam Levy Sells 36% Of Holding - simplywall.st
Mineralys Therapeutics to Announce Second Quarter 2025 Financial Results and Host Conference Call on Tuesday, August 12, 2025 - The Manila Times
Momentum Screeners Rank Mineralys Therapeutics Inc. in Top 5 TodaySwing Trading Plan With Smart Signals in Review - beatles.ru
Support Zone Holds Steady for Mineralys Therapeutics Inc. After DipLow Capital High Return Stock Plans Reviewed - metal.it
Mineralys Therapeutics to Announce Second Quarter 2025 - GlobeNewswire
What drives Mineralys Therapeutics Inc. stock priceAchieve consistent profits with smart trading - Jammu Links News
How many analysts rate Mineralys Therapeutics Inc. as a “Buy”Explosive trading growth - Jammu Links News
What are Mineralys Therapeutics Inc. company’s key revenue driversBuild a diversified portfolio for risk management - Jammu Links News
What catalysts could drive Mineralys Therapeutics Inc. stock higher in 2025Unlock exclusive trading tools and resources - Jammu Links News
Mineralys Therapeutics Inc. Stock Analysis and ForecastAchieve breakthrough investment performance - Jammu Links News
Is Mineralys Therapeutics Inc. stock overvalued or undervaluedBuild wealth steadily with smart stock selection - Jammu Links News
What is the dividend policy of Mineralys Therapeutics Inc. stockCapitalize on market trends with confidence - jammulinksnews.com
How volatile is Mineralys Therapeutics Inc. stock compared to the marketMaster the art of timing market moves - Jammu Links News
How strong is Mineralys Therapeutics Inc. company’s balance sheetCapitalize on fast-moving trading opportunities - Jammu Links News
Is it the right time to buy Mineralys Therapeutics Inc. stockBuild a balanced portfolio for long-term success - Jammu Links News
CFO & Secretary Of Mineralys Therapeutics Sold 36% Of Their Shares - 富途牛牛
Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and Development of Newer Therapies During the Study Period (2020-2034) | DelveInsight - Yahoo Finance
Mineralys Therapeutics Insider Sold Shares Worth $1,077,477, According to a Recent SEC Filing - 富途牛牛
Mineralys Therapeutics CFO Adam Levy sells $1m+ in shares By Investing.com - Investing.com Australia
Mineralys Therapeutics CFO Adam Levy sells $1m+ in shares - Investing.com
Mineralys CFO Sells 12946 Shares at $14.04/Share on 2025-07-28 - AInvest
What analysts say about Mineralys Therapeutics Inc. stock outlookRisk Adjusted Technical Entry Plan Gains Followers - beatles.ru
Why Mineralys Therapeutics Inc. stock attracts strong analyst attentionNews Based Entry Opportunity Alerts Detected - beatles.ru
Will Mineralys Therapeutics Inc. stock split in the near futureTrend Analysis for Safer Trades Gains Popularity - metal.it
Aldosterone Synthase Inhibitors Market is evolving rapidly - openPR.com
Intrinsic Value of Mineralys Therapeutics Inc. Stock: Is It Undervalued or OvervaluedAccurate Technical Trend Reversal Picks Detected - metal.it
Is Mineralys Therapeutics Inc. a growth stock or a value stockExceptional market positioning - Jammu Links News
Why is Mineralys Therapeutics Inc. stock attracting strong analyst attentionOutstanding trading profits - Jammu Links News
What are the latest earnings results for Mineralys Therapeutics Inc.Get real-time updates on market trends - Jammu Links News
What are the technical indicators suggesting about Mineralys Therapeutics Inc.Unrivaled growth potential - Jammu Links News
What is Mineralys Therapeutics Inc. company’s growth strategyPowerful market insights - jammulinksnews.com
Published on: 2025-07-27 22:40:23 - Jammu Links News
What makes Mineralys Therapeutics Inc. stock price move sharplyFree Investment Group - metal.it
Does Mineralys Therapeutics, Inc. (MLYS) Have the Potential to Rally 154.21% as Wall Street Analysts Expect? - Zacks Investment Research
What analysts say about Mineralys Therapeutics Inc. stockSuperior risk-adjusted returns - PrintWeekIndia
Mineralys Therapeutics, Inc. (MLYS) Upgraded to Buy: Here's Why - Yahoo Finance
Is Mineralys Therapeutics Inc. stock overhyped or has real potentialHigh-octane financial growth - jammulinksnews.com
Mineralys Therapeutics Inc (MLYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):